CurisFRA:CUS0 +1.64%49 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:CUS0 with a GF Score™ of 49/100 and a GF Value™ of €1.07 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, Curis ranks worse than 71.01% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Curis's EBITDA for the
three
months ended in Mar. 2026 was €-9.96 Mil. Curis's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, Curis's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
Curis (FRA:CUS0) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Curis EBITDA Margin % Related Terms
Curis EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Curis's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CUS0 vs HOWL, TRAW, CVM: EBITDA Margin % Comparison
For the Biotechnology subindustry, Curis's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Curis's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Curis's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis (FRA:CUS0) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Curis and its competitors. According to the industry distribution chart, Curis ranks #671 out of 945 companies in the Biotechnology industry, placing it in the top 71%.
Is Curis' EBITDA Margin % too high?
Curis' current EBITDA Margin % is 0.00%. Based on the distribution chart, Curis ranks #671 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Curis has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Curis' EBITDA Margin % compare to HOWL and TRAW?
According to the Biotechnology industry distribution chart, Curis ranks #671 out of 945 companies for EBITDA Margin %. This places Curis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Curis and its competitors. Curis's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis stock overvalued right now?
Based on GuruFocus' analysis, Curis (FRA:CUS0) is currently considered Possible Value Trap. The stock's GF Value™ is €1.07, compared to a current price of €0.37 — trading 65.2% below its estimated fair value. The current EBITDA Margin % is 0.00%. Curis' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Curis (FRA:CUS0), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curis (FRA:CUS0) Overvalued in 2026?
Based on GuruFocus' analysis, Curis stock appears to be undervalued.
The current stock price of €0.37 is trading 65.2% below its estimated GF Value™ of €1.07.
GuruFocus considers Curis to be Possible Value Trap.
Key valuation signals for FRA:CUS0:
EBITDA Margin %: 0.00%
GF Value™: €1.07 vs. price of €0.37 (65.2% below fair value)
No single metric tells the full story. See the FRA:CUS0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
49GF Score
Get the complete analysis for FRA:CUS0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CUS0 has been successfully added to your 
